Robert C. Goeltz II, CFO of Arcus Biosciences ($RCUS), made five open market sales of company shares over the past year, totaling nearly $657,000. His latest sale occurred on December 31, 2025. These transactions rank 5,895th out of 11,678 individual insiders, trailing the average sale value of $8.6 million and 6.4 sales per insider. Goeltz reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 23, 2026 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Common Stock | 24000 | $0.00 | 91,924.0000 | 107,973,536 | 35.33% | 0.02% |
| Jan. 23, 2026 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Stock Option (right to buy) | 96000 | $0.00 | 96,000.0000 | 107,973,536 | 9999.99% | 0.09% |
| Dec. 31, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 6552 | $23.38 | 67,924.0000 | 107,973,536 | 8.80% | 0.01% |
| Dec. 17, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 5960 | $22.16 | 74,476.0000 | 107,973,536 | 7.41% | 0.01% |
| Dec. 16, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 6702 | $21.88 | 80,436.0000 | 107,973,536 | 7.69% | 0.01% |
| Nov. 26, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 5000 | $25.00 | 87,138.0000 | 107,973,536 | 5.43% | 0.00% |
| Oct. 28, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 5000 | $20.00 | 92,138.0000 | 107,973,536 | 5.15% | 0.00% |
| Jan. 23, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Common Stock | 37000 | $0.00 | 97,138.0000 | 0 | 61.53% | 0.00% |
| Jan. 23, 2025 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 31, 2024 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 3594 | $15.00 | 60,138.0000 | 0 | 5.64% | 0.00% |
| Dec. 15, 2024 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | F | Common Stock | 10099 | $16.08 | 63,732.0000 | 0 | 13.68% | 0.00% |
| Jan. 23, 2024 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Common Stock | 22000 | $0.00 | 73,831.0000 | 0 | 42.45% | 0.00% |
| Jan. 23, 2024 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Common Stock | 21300 | $0.00 | 73,131.0000 | 0 | 41.10% | 0.00% |
| Jan. 23, 2024 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | A | Stock Option (right to buy) | 86600 | $0.00 | 86,600.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2024 | Arcus Biosciences, Inc. | $RCUS | Goeltz II Robert C. | Chief Financial Officer | S | Common Stock | 2004 | $20.00 | 51,831.0000 | 0 | 3.72% | 0.00% |